Search results
Results from the WOW.Com Content Network
Investors are optimistic about Edwards Lifesciences (EW) on continued strong adoption of the SAPIEN 3 Ultra platform and the PASCAL system.
For premium support please call: 800-290-4726 more ways to reach us
Edwards Lifesciences (EW) expects full-year 2022 underlying sales growth in the mid-single-digit range on the back of strength in demand for products used in more intense surgeries.
Stock name Symbol Country of origin E-Commerce China DangDang Inc. DANG: China: E-House (China) Holdings Limited EJ: China: E. I. du Pont de Nemours and Company (DuPont) DD: US E. I. du Pont de Nemours and Company (DuPont) DD.PRA: US E. I. du Pont de Nemours and Company (DuPont) DD.PRB: US The E. W. Scripps Company: SSP: US Eagle Materials Inc ...
Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Large-Cap Growth Fund posted a return of 27.86% for the quarter, outperforming its ...
The EW Group GmbH (also known as the Erich Wesjohann Group), headquartered in Visbek, Germany, is a global family owned holding, which integrates more than 300 active subsidiaries. The company is operating primarily at the beginning of the value chain, including animal and plant breeding, animal health and diagnostics.
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter. [4]
For premium support please call: 800-290-4726 more ways to reach us